
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is viewed favorably because Ibtrozi already has a meaningful commercial head start in ROS1+ NSCLC, with durable efficacy and a differentiated safety profile that may support physician adoption despite lighter-than-expected 3Q26 revenue of $27.5M and competitive pressure. The investment case is further strengthened by safusidenib, which is seen as the main value creator thanks to recent BTD momentum, a 79.1% 36-month PFS rate in Japanese patients, and development milestones still on track for 2027 data, including the expanded SIGMA study. With the company described as well capitalized and its valuation anchored by two assets, Ibtrozi and safusidenib, the combination of near-term launch optionality and long-duration pipeline upside supports a constructive fundamental outlook.
Bears say
Nuvation Bio is facing a weaker-than-expected launch profile for Ibtrozi, with revenue of $27.5M falling below both the $30.5M estimate and the Street’s $29.2M as the overall ROS1 TKI market declined 15% and new patient starts stayed flat at about 160, including fewer critical 1L adds. The business also faces commercialization friction from a small, competitive indication, potential dose-dependent pricing pressure, and safety concerns such as edema, dyspnea, and weight gain that could limit adoption and prolong patient stacking. Beyond the launch, the company’s outlook is further burdened by early-stage pipeline execution risk, dependence on Japan-linked revenue streams, potential dilution from additional financing, and repayment obligations tied to the Sagard Health Partners deal.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Nuvation Bio (NUVB) Forecast
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares